top of page
Platten 2_bearbeitet_bearbeitet_bearbeit

Prof. Dr. Michael Platten

Project C1

Chairman, Department of Neurology,

University Medical Center Mannheim, Heidelberg University &

CCU Neuroimmunology and Brain Tumor Immunology,

German Cancer Research Center Heidelberg

​

michael.platten(at)umm.de

Michael Platten is head of the CCU Neuroimmun-ology and Bain Tumor Immunology at DKFZ. He obtained his MD from the Department of Neuropathology at the University of Bonn and did his residency at the Department of Neurology, Tübingen University. Michael pursued postdoctoral fellowships in Neuroimmunology  at Stanford University and in Neurooncology at Tübingen University before becoming a Helmholtz Young Investigator at the Department of Neurology, University Hospital Heidelberg and German Cancer Research Center. Currently, he is the Chairman of the Department of Neurology at the Medical Faculty Mannheim, Heidelberg University and Head of the CCU Brain Tumor Immunology at DKFZ.

Qualifications and Scientific Curriculum

1998

2002-2004

2006

2010-2015

since 2013

since 2016

MD, University of Bonn, Germany

​

Postdoctoral Research Fellow, Stanford University, Stanford, USA

​

Board certified Neurologist

​

Associate Professor of Neuroimmunology, Heidelberg University, Germany

​

Head of Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Germany

​

Full Professor of Neurology and Chairman of the Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Germany

Selected publications

​

  1. Friedrich M*, Sankowski R*, Bunse L*, Kilian M, Green E, Ramallo-Guevara C, Pusch S, Poschet G, Sanghvi K, Hahn M, Bunse T, Münch P, Sonner JK, von Landenberg A, Cichon F, Aslan K, Trobisch T, Schirmer L, Abu-Sammour D, Kessler T, Ratliff M, Schrimpf D, Sahm F, Hopf C, Heiland DH, Schnell O, Beck J, Böttcher C, Fernandez-Zapata C, Priller J, Heiland S, Gutcher I, Quintana F, von Deimling A, Wick W, Prinz M*, Platten M*: Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nat Cancer. 2:723–740, 2021. (*equal contribution)

  2. Platten M, Bunse l, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens G, Breckwoldt M, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W: A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 592:463-468, 2021.

  3. Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, Núñez NG, De Feo D, Kickingereder P, Fischer M, Green E, Sadik A, Friedrich M, Sanghvi K, Kilian M, Cichon F, Wolf L, Jähne K, von Landenberg A, Bunse L, Sahm F, Schrimpf D, Meyer J, Alexander A, Brugnara G, Röth R, Pfleiderer K, Niesler B, von Deimling A, Opitz CA, Breckwoldt MO, Heiland S, Bendszus M, Wick W, Becher B, Platten M: Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun. 11:931, 2020.

  4. Sonner JK*, Keil M*, Falk-Paulsen M*, Mishra N, Rehman A, Kramer M, Deumelandt K, Röwe J, Sanghvi K, Wolf L, von Landenberg A, Wolff H, Bharti R, Oezen I, Lanz TV, Wanke F, Tang Y, Brandao I, Mohapatra S, Epping L, Grill A, Röth R, Niesler B, Meuth SG, Opitz CA, Okun JG, Reinhardt C, Kurschus F, Wick W, Bode HB, Rosenstiel P*, Platten M*: Dietary tryptophan links encephalitogenicity of autoreactive T cells with gut microbial ecology. Nat Commun. 10:4877, 2019. (*equal contribution)

  5. Bunse L*, Pusch S*, Bunse T*, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger M, Harter P, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende CM, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suva M, Niemeyer BA, von Deimling A, Wick W, Platten M: Suppression of antitumor T cell immunity by the oncometabolite R-2-hydroxyglutarate. Nat Med. 24:1192-1203, 2018. (*equal contribution)

  6. Schumacher T*, Bunse L*, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stefanovic S, Riemer AB, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M: A vaccine targeting mutant IDH1 induces antitumor immunity. Nature. 512:324-327, 2014. (*equal contribution)

  7. Opitz CA*, Litzenburger UM*, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M: An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 478:197-203, 2011. (*equal contribution)

bottom of page